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Objective: F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is
now a procedure of proven clinical value in the staging of primary lung cancer. This
study evaluated the role of PET in the preoperative assessment of resectable lung
metastases.
Methods: Eighty-six patients with previously treated malignancy and proven or
suspected lung metastases, deemed resectable at computed tomography scan, were
investigated with 89 preoperative PET procedures. Primary tumor sites were:
gastrointestinal in 32 cases, sarcoma in 13, urologic in 14, breast in 8, head and neck
in 7, gynecologic in 5, thymus in 5, other in 5. Seventy lung resections were
performed in 68 patients of whom only 54 proved to be lung metastasis, 7 were
primary lung tumors, and 9 were benign lesions.
Results: In 19 cases (21%) lung surgery was excluded on the basis of PET scan
results due to extrapulmonary metastases (11 cases), primary site recurrence (2),
mediastinal adenopathy (2), or benign disease (4). All mediastinal node metastases
(7 cases) were detected by PET with a sensitivity, accuracy, and negative predictive
value for mediastinal staging of 100%, 96%, and 100%, respectively, versus 71%,
92%, and 95% of the computed tomography scan. In the group of patients who
underwent lung resection, PET sensitivity for detection of lung metastasis was 87%.
Conclusions: PET scan proved to be a valuable staging procedure in patients with
clinically resectable lung metastasis and changed the therapeutic management in a
high proportion of cases.
The surgical treatment of isolated pulmonary metastases has becomea widely accepted procedure, with low morbidity and mortality.1,2The oncologic criteria for selection of surgical candidates and themain factors affecting prognosis were investigated in large series ofcases.3,4 Nonetheless, only 30% of patients with isolated and ana-tomically resectable lung metastases can be cured by surgery, and
there is a need to improve the preoperative selection for optimal candidates.
The value of positron emission tomography (PET) in preoperative staging has
been clearly demonstrated for primary lung cancer,5-8 where PET assessment of
mediastinal and extrathoracic occult metastasis avoids unnecessary surgery in about
10% of patients.
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Presence of extrathoracic disease in patients with lung
metastasis including primary site relapse represents, with
rare exceptions, the main reason for exclusion from surgical
treatment. Recently, mediastinal lymph node staging has
been suggested as another important prognostic factor in
otherwise resectable lung metastases.3,9,10 In this view, ac-
curate staging of both extrathoracic deposits and mediasti-
nal nodes becomes essential to improve selection of surgical
candidates.
Preoperative PET can modify the clinical management of
patients with lung metastasis by detecting occult metastases
in other organs, primary site recurrence, nodal spread at the
hilar or mediastinal level, as well as by differentiating
malignant from benign pulmonary nodules. PET can also
help to exclude distant metastases in patients with equivocal
evidence at computed tomography (CT) scan or ultrasound.
The aim of this study was to evaluate the clinical value of
F-18 fluorodeoxyglucose (FDG) PET in addition to spiral
CT for preoperative staging of lung metastasis.
Patients and Methods
Patients
Patients with previously treated malignancy and proven or sus-
pected lung metastases deemed resectable at CT scan were eval-
uated with FDG-PET. A total of 86 patients were studied with 89
PET procedures between August 1998 and December 2000. There
were 48 men and 38 women with a mean age of 60 years. Median
disease-free survival was 24 months. Primary tumor site of all
patients is presented in Table 1. Thirty patients (35%) had previ-
ously submitted to lung metastasectomy and presented recurrent
lung metastasis. All patients were evaluated with contrast spiral
CT of the chest and abdomen and additional imaging tests, such as
nuclear magnetic resonance imaging or ultrasound, in case of
symptoms or signs suggestive of distant metastasis or primary site
recurrence. Resectability was based on the following criteria:
primary tumor previously cured or curable, no evidence of ex-
trapulmonary metastases, complete removal of all pulmonary me-
tastases feasible, planned resection volume tolerable by the patient.
Among patients who underwent resection for lung metastases,
7 had received preoperative chemotherapy within 3 months of
metastasectomy.
PET
Images were acquired with a General Electric Advance PET scan-
ner (General Electric Medical Systems, Milwaukee, Wis) 1 hour
after injection of approximately 370 MBq of F-18 FDG. Each
patient was imaged with arms over the head, covering a field of
view from neck to pelvis. A transmission scan was then performed
on the thorax region to measure attenuation. Raw data were cor-
rected for measured attenuation by segmented transmission data
and then reconstructed in transaxial images by an iterative algo-
rithm with 16 subset and order 4. Parametric standard uptake value
(SUV) transaxial images were obtained as follows: SUV  (pixel-
by-pixel activity in becquerels per cubic centimeter)/(injected dose
in megabecquerls per body weight in kilograms). Circular regions
of interest (ROIs) were manually drawn on transaxial images
around the focal FDG-uptake area. No correction for partial-
volume effect was performed. Mean value of maximum SUV of
different slices of each nodule was considered for statistical anal-
ysis. Data on SUV were available for 70 of 89 PET procedures.
Surgery and Pathologic Results
Seventy lung resections were performed in 68 patients with the
following pathologic results: 54 lung metastases, 7 primary lung
tumors, and 9 benign lesions. Of 54 patients with lung metastasis,
41 had monolateral lung resection and 13 bilateral resection. A
single lung metastasis was present in 26 patients, from 2 to 5
metastases in 21 patients, and more than 5 in 7 patients. A proper
lymph node sampling was performed in 31 of 54 patients with
proven lung metastasis: this included an average of 12.2 nodes and
at least 1 hilar and 1 mediastinal station. In an additional 19
TABLE 1. Primary site tumor in 89 cases of PET scan performed in 86 patients with suspected lung metastases divided for
pathological results in case of lung resection (lung metastasis, second primary tumor, and benign lesion) and for causes
of exclusion from surgery (distant metastasis, local recurrence, mediastinal node metastases, and benign lung lesions)
Surgery No surgery
Total LM SPT Benign DM LR Med Benign
Overall 89 54 7 9 11 2 2 4
Primary site
Colorectal 32 24 1 3 3 1 — —
Sarcoma 17 12 — — 3 1 1 —
Urologic 14 7 2 — 2 — 1 1
Breast 6 2 2 1 1 — — —
Head/neck 7 3 1 1 — — — 1
Gyn 4 2 — 1 1 — — —
Thymus 5 3 — — 1 — — 1
Testis 2 1 — 1 — — — —
Skin/Mel 3 — 1 1 — — — 1
Teratoma 1 — — 1 — — — —
LM, Confirmed lung metastasis; SPT, second primary tumor; DM, distant metastasis; LR, local recurrence; MED, mediastinal node metastasis; Gyn,
gynecologic tumor; Mel, melanoma.
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patients, the mediastinal involvement was assessed by follow-up
data (8 of these had 1 hilar station pathologically evaluated,
average 1.5 nodes). Nodal status was not available in 4 patients.
Statistical Analysis
Comparisons of percentage of positive nodes by histologic type
and sensitivity by histologic type or by nodule size category were
done by the Fisher exact test. Mean SUV values were compared
taking into account nodule size by regression analysis. All analyses
were done with SAS software (SAS, Inc, Cary, NC).
Results
In 19 of 89 cases (21%) lung surgery was not performed on
the basis of PET results, which showed extrapulmonary
metastasis in 11 cases, primary site recurrence in 2, medi-
astinal adenopathy in 2, benign lung nodule in 4 (Table 1).
Sites of local recurrences were colon cancer in 1 patient and
sarcoma of the arm in another. Of the 11 cases of distant
metastases, 5 bone lesions were confirmed by rib biopsy (2),
magnetic resonance imaging (MRI) (2), or bone scan (1); 2
adrenal lesions were confirmed by CT; 1 chest wall metas-
tasis with needle biopsy; 1 pancreatic metastasis by MRI; 1
liver and abdominal node metastases were confirmed by
clinical follow-up only. Of the 2 mediastinal nodes, 1 was
confirmed by mediastinoscopy and the other by progression
of N2 disease at follow-up. In the 4 cases excluded from
surgery, benignity was assessed by clinical follow-up, with-
out biopsy.
Among patients submitted to lung resection (70), in 2
cases clinical management was changed by PET detection
of a colon cancer recurrence that was resected before lung
metastasectomy and 1 liver metastases that was treated after
lung surgery. In 2 further cases, distant metastases were
identified by PET in the liver and pelvis, but lung metasta-
sectomy was performed due to negative CT scan. Later
follow-up confirmed the true positivity of PET staging, with
tumor progression at these distant sites. There were 3 false-
negative PET extrapulmonary sites of disease: a brain me-
ningioma, a pleural micrometastasis (diameter 1-3 mm), and
a small breast cancer. A false-positive PET at distant sites
occurred in 7 patients: bone hot spots in 2 patients (spine,
chest wall), site of previous surgical resection in 1 patient
(pelvis), neck and abdominal lymph nodes in 2 cases, and
prostatic hyperplasia in 1 case. PET sensitivity, specificity,
and accuracy for detection of distant deposits were 85%,
90%, and 89%, respectively.
Among patients subjected to lung metastasectomy, all
cases (7/50, 14%) of mediastinal nodes involvement were
detected by PET, with only 2 cases of false-positive PET at
the mediastinal level. Overall sensitivity, accuracy, and
negative predictive value at the mediastinal level were
greater that those of CT scan (100%, 96%, and 100% vs
71%, 92%, and 95%, respectively, Table 2). In 2 cases of
positive mediastinal PET and negative CT scan of the chest,
we could have avoided exploratory thoracotomy by con-
firming PET results through mediastinoscopy. In the other 5
cases, preoperative detection of localized mediastinal dis-
ease by PET allowed a better approach by lung metastasec-
tomy combined with radical mediastinal lymphadenectomy
or mediastinal adjuvant radiotherapy. In 2 additional cases
PET detection of major mediastinal involvement led to
exclusion from surgery. At the hilar station there were 3
false-negative PET metastases (sensitivity 40%) and 5 false-
negative CT scans (sensitivity 0%) (Table 2). Positive
lymph nodes occurred in 23% of patients with epithelial
tumors (13% mediastinal) and 17% of patients with sarcoma
metastases (17% mediastinal).
PET was positive at the pulmonary level in 47 of 54
(87%) patients who underwent metastasectomy. Table 3
describes sensitivity of PET in relation to lung lesions size
and primary tumor type. Only 40% of nodules smaller than
10 mm were PET positive; sensitivity increased to 90% for
nodules between 10 to 20 mm and 94% for nodules greater
than 20 mm (P  .0149). PET sensitivity was 92% for
colorectal cancer, 86% for urologic neoplasms, 75% for
sarcomas, and 50% for breast cancer. No significant asso-
ciation between sensitivity and tumor type was evident (P
TABLE 2. Results of PET and CT detection of hilar and mediastinal node metastasis in 50 patients with lung metastasis
submitted to lymph node sampling (31) or follow-up study (19)
No. of
patients TP FN TN FP Sens (%) Spec (%) Accur (%) PPV (%) NPP (%)
PET
Med 50 7 0 41 2 100 95 96 78 100
Hil 50 2 3 44 1 40 98 92 66 94
M or H 50 8 3 36 3 72 92 88 72 92
CT
Med 50 5 2 41 2 71 95 92 71 95
Hil 50 0 5 44 1 0 98 88 0 90
M or H 50 5 6 36 3 45 92 82 62 86
TP, True-positive; FN, false-negative; TN, true-negative; FP, false-positive; PPV, positive predictive value; NPP, negative predictive value; Med, mediastinal;
Hil, hilar; M or H, mediastinal or hilar.
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.5). Among the 9 patients with resected benign lesions, there
were 7 false-positive PET and 2 true-negative results. In the
remaining 4 patients with benign disease, lung resection was
avoided based on the negative PET results. The overall
sensitivity with respect to pulmonary metastases was then
87%, specificity 46%, positive predictive value 87%, neg-
ative predictive value 46%.
Table 4 describes the analysis of SUV data in relation to
pathologic characteristics. Mean SUV was higher in pa-
tients with colon cancer than in those with sarcoma, but no
significant difference was evident between these 2 tumor
types. A borderline P value was demonstrated when com-
paring SUV of benign and malignant lesions (.08), but it
increased to .14 when adjusting SUV for nodule size. Mean
SUV was lower in the 7 patients who had received preop-
erative chemotherapy within 3 months of lung metastasec-
tomy (2.7  2.2 vs 4.5  3.5, P  .2), but SUV reduction
did not affect sensitivity, which remained 100% in this
subset of patients.
Discussion
On the basis of CT scan staging, lung metastasectomy can
achieve permanent cure and long-term survival in over 30%
of cases.1-4 Presence of extrathoracic deposits in patients
with lung metastasis is the main reason for exclusion from
salvage surgery, whereas only recent reports have empha-
sized the importance of mediastinal staging in lung metas-
tasis, indicating poor prognosis if nodal metastases are
present.3,9,10
The main result of our study was the high frequency of
positive extrapulmonary PET foci. This observation has
modified the treatment plan in over 20% of patients. PET
detection of occult distant metastases or recurrence at the
primary site avoided unnecessary lung resections or
changed therapeutic strategy with prior treatment of ex-
trathoracic disease such as combined staged liver and lung
metastasectomy. Sensitivity and specificity for detection of
extrapulmonary deposits in patients with lung metastases
were comparable with those reported by Pieterman and
colleagues5 in potentially resectable lung cancer (85% and
90% vs 82% and 93%, respectively). PET false-negatives
were limited to a brain meningioma, a small breast cancer,
and a pleural metastasis. In the present study PET was not
able to downstage patients by excluding equivocal evidence
of distant metastasis on initial CT staging.
In this series all mediastinal node metastases were de-
tected by PET with a sensitivity and accuracy greater than
contrast CT scan. Preoperative knowledge of mediastinal
node involvement may allow a better management of these
patients, as it is an indication for preoperative chemotherapy
and radical lymphadenectomy. On the other hand, the
knowledge on hilar node metastasis may be of great impor-
tance in planning an anatomic resection, such as segmen-
tectomy or lobectomy, instead of a simple wedge or preci-
sion resection.
In our series, mediastinal node involvement was ob-
served in 14% of patients with resected lung metastasis,
which reproduces exactly the data reported by Loehe and
colleagues.9 In addition, our study confirmed the high neg-
ative predictive value of PET in mediastinal staging, similar
to that reported in lung cancer (100% present study vs 95%
Pieterman and colleagues5.) On the other hand, given the
low positive predictive value on mediastinal staging (78%),
a confirmation with surgical mediastinoscopy or transbron-
chial biopsy is still necessary before excluding patients from
surgery in the case of positive PET at the mediastinal level.
Although mediastinal node metastases may have a lesser
TABLE 3. PET sensitivity in lung metastasis
PET positive PET negative % P value*
Overall sensitivity 47 7 87
Sensitivity by nodule size†
10 mm 2 3 40
11-20 mm 18 2 90
21 mm 27 2 93 0.0149
Sensitivity by histology
Colon 22 2 92
Urologic 6 1 86
Sarcoma 9 3 75
Head/neck 3 0 100
Thymus 3 0 100
Breast 1 1 50
Gynecologic 2 0 100
Testis 1 0 100 0.51
*Fisher exact extension associated P value.
†Maximum nodule size was considered for calculating sensitivity in pa-
tients with multiple nodules.
TABLE 4. Histology of lung lesions and SUV
Histology
No. of
patients
No. of
lesions*
Mean
SUV SEM
Median
SUV
Lung metasases 40 53 4.3 0.5 3.4
Colorectal 20 28 4.3 0.7 3.5
Sarcoma 7 7 3.7 1.4 2.7
Urologic 5 7 5.5 1.4 3.4
Breast 2 2 4.2 4.2 4.2
Head/neck 1 3 1.3 0.2 1.2
Gynecologic 2 3 6.6 2.4 8.4
Thymus 3 3 4.0 0.6 3.7
Second primary 5 5 3.1 0.8 1.8
Carcinoid 2 2 1.7 0.1 1.7
Squamous 1 1 2.8 NA 2.8
Adenoca 1 1 1.7 NA 1.7
Sclc 1 1 7.3 NA 7.3
Benign 5 5 2.2 1.1 1.5
Malignant versus benign: P 0.085; colorectal versus sarcoma: P 0.713.
*Only resected lesions with SUV data and pathological size available were
considered for analysis.
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prognostic relevance in thyroid or kidney cancer, this was
not the case of the 2 patients excluded from surgery in our
series (sarcoma and bladder cancer). Sensitivity of PET for
detection of hilar nodes was only 40%, but it was higher
than CT scan. If we consider the contribution of PET scan
on nodal staging, the overall change in patient management
could be higher than 30% of cases.
With the increasing sensitivity of spiral CT the main
limitation of radiologic assessment will become the differ-
ential diagnosis of small undetermined pulmonary nodules
in patients with previous malignancy, rather than presence
of occult lung metastasis. Lucas and colleagues11 reported
an 86% sensitivity rate of FDG-PET in detection of lung
metastases from soft tissue tumors and a sensitivity of 100%
of chest CT. Lowe and colleagues12 reported sensitivity and
specificity rates of 92% and 90%, respectively, in identify-
ing malignant features in undetermined lung nodules in
patients with or without previous malignancy. In the present
study, the overall PET sensitivity on lung metastasis was
87% and the capability of a noninvasive method to differ-
entiate benign from malignant nodules avoided biopsy in 4
cases. On the other hand, the high rate of false-positive PET
caused by chronic inflammation or infection and the low
specificity and negative predictive value (46%) still repre-
sent a limitation of this technique.13 Our results, in disagree-
ment with previous observations,12 could be partially attrib-
utable to the absence of a cutoff value of SUV to
differentiate benign from malignant nodules.
A significantly lower sensitivity was evident for nodules
of less that 1 cm (40% vs 90%). PET tended to be more
sensitive in the case of colon cancer lesions than in sarco-
mas, but the difference was not statistically significant. In
agreement with prior reports, PET accuracy was similar to
that of spiral CT in detection of lung nodules11,14 and the
use of PET did not supply any additional information to
alter the surgical approach (ie, bilateral vs monolateral).
Analysis of SUV in different tumor types has shown
higher value of SUV in colon cancer metastasis than in
sarcomas (not significant). Comparison of mean SUV value
in malignant nodules and benign ones demonstrated a bor-
derline P value, which became clearly not significant when
adjusting SUV data for nodule size.
In conclusion our experience demonstrates that PET can
improve the management of resectable lung metastases in a
high proportion of patients. Our findings support the impor-
tant role of PET in the selection of surgical candidates for
lung metastasectomy with the aims of improving detection
of extrathoracic disease, identifying nodal metastases, and
increasing the accuracy of differential diagnosis of benign
from malignant lung lesions.
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